Biogen is a successful biotech company at a crossroads. CEO John Mullen about how technological changes in the research function are introduced to form larger business decisions. This world, operating in the biotech company had changed greatly in recent years. Parts of biology are evolving rapidly from being an individualistic, wet laboratory, bench-science driven field in the direction of where scientists manipulate huge amounts of data and the research steps in a split … Read more »

Biogen is a successful biotech company at a crossroads. CEO John Mullen about how technological changes in the research function are introduced to form larger business decisions. This world, operating in the biotech company had changed greatly in recent years. Parts of biology are evolving rapidly from being an individualistic, wet laboratory, bench-science driven field in the direction of where scientists manipulate huge amounts of data and the research is divided into steps like a factory production process. At the same time was the cost of developing a drug and bringing it to market ballooned from an estimated $ 231 million in 1991 to $ 802 million in 2000. Biogen was in the adoption of new genomics tools conservative. This case describes how to bring the company decided to house the latest genomics and in silico tools. Regarding the discovery and research phase of drug development The company has also restructured its research strategy. As new tools and early-stage research began to bear fruit, they realized that Mullen significant changes on the street implies for other parts of Biogen.
«Hide

from
Juan Enriquez,
Gary P. Pisano,
Gaye L. Bok
Source: Harvard Business School
30 pages.
Release Date: 09 April 2002. Prod #: 602122-PDF-ENG
In vivo in vitro, in silico: Dealing with Tidal Waves of data at Biogen HBR case solution

[related_post themes="flat"]